ribociclib
novartis
['maintain trial', 'ribociclib']
maintain trial shows the benefit of ribociclib and switching endocrine therapy after progression to cdk4/6i plus ai. very interesting. what next #asco22 
MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program